Industry Research Reports

Home > Reports > Pharma & Healthcare > Antihyperuricemic Agents - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Antihyperuricemic Agents - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-11

Pages: 167 Pages

Report ld: 2636003

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Antihyperuricemic agents are also called anti-gout drugs. These drugs correct the overproduction or underexcretion of uric acid.

The global market for Antihyperuricemic Agents was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Antihyperuricemic Agents, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Antihyperuricemic Agents by region & country, by Type, and by Application.

The Antihyperuricemic Agents market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihyperuricemic Agents.

Market Segmentation

Report Metric
Details
Report Title
Antihyperuricemic Agents - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Antihyperuricemic Agents Companies Covered
Takeda Pharmaceuticals, Hikma, Wockhardt, West Ward Pharmaceuticals, Rhea Pharmaceutical, Medinova, Odan Laboratories, TEIJIN, Casper Pharma, Dr. Reddys Laboratories, Teva, Zydus Pharmaceuticals, Mylan, Sun Pharmaceutical, APOTEX, NorthStar Healthcare, Ipca Laboratories, Accord Healthcare, Gentec Pharmaceutical Group, Indoco Remedies, Lupin, Waterstone Pharmaceuticals, ALP Pharm, Jiangsu Hengrui Medicine, Jiangsu Wanbang Biopharmaceuticals, Hangzhou Zhuyangxin Pharmaceutical, YiChang HEC ChangJiang Pharmaceutical, KPC Pharmaceuticals, Tonghua Limin, Beijing Jialin Pharmaceutical
Global Antihyperuricemic Agents Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antihyperuricemic Agents Market, Segment by Type
Inhibit Uric Acid Production Agents

Promote Uric Acid Excretion Agents

Others
Global Antihyperuricemic Agents Market, Segment by Application
Hospital Pharmacies

Retail Pharmacies

Online Pharmacies
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antihyperuricemic Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Antihyperuricemic Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Antihyperuricemic Agents in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Antihyperuricemic Agents Product Introduction
    1.2 Global Antihyperuricemic Agents Market Size Forecast
        1.2.1 Global Antihyperuricemic Agents Sales Value (2019-2030)
        1.2.2 Global Antihyperuricemic Agents Sales Volume (2019-2030)
        1.2.3 Global Antihyperuricemic Agents Sales Price (2019-2030)
    1.3 Antihyperuricemic Agents Market Trends & Drivers
        1.3.1 Antihyperuricemic Agents Industry Trends
        1.3.2 Antihyperuricemic Agents Market Drivers & Opportunity
        1.3.3 Antihyperuricemic Agents Market Challenges
        1.3.4 Antihyperuricemic Agents Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Antihyperuricemic Agents Players Revenue Ranking (2023)
    2.2 Global Antihyperuricemic Agents Revenue by Company (2019-2024)
    2.3 Global Antihyperuricemic Agents Players Sales Volume Ranking (2023)
    2.4 Global Antihyperuricemic Agents Sales Volume by Company Players (2019-2024)
    2.5 Global Antihyperuricemic Agents Average Price by Company (2019-2024)
    2.6 Key Manufacturers Antihyperuricemic Agents Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Antihyperuricemic Agents Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Antihyperuricemic Agents
    2.9 Antihyperuricemic Agents Market Competitive Analysis
        2.9.1 Antihyperuricemic Agents Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Antihyperuricemic Agents Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihyperuricemic Agents as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Inhibit Uric Acid Production Agents
        3.1.2 Promote Uric Acid Excretion Agents
        3.1.3 Others
    3.2 Global Antihyperuricemic Agents Sales Value by Type
        3.2.1 Global Antihyperuricemic Agents Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Antihyperuricemic Agents Sales Value, by Type (2019-2030)
        3.2.3 Global Antihyperuricemic Agents Sales Value, by Type (%) (2019-2030)
    3.3 Global Antihyperuricemic Agents Sales Volume by Type
        3.3.1 Global Antihyperuricemic Agents Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Antihyperuricemic Agents Sales Volume, by Type (2019-2030)
        3.3.3 Global Antihyperuricemic Agents Sales Volume, by Type (%) (2019-2030)
    3.4 Global Antihyperuricemic Agents Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital Pharmacies
        4.1.2 Retail Pharmacies
        4.1.3 Online Pharmacies
    4.2 Global Antihyperuricemic Agents Sales Value by Application
        4.2.1 Global Antihyperuricemic Agents Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Antihyperuricemic Agents Sales Value, by Application (2019-2030)
        4.2.3 Global Antihyperuricemic Agents Sales Value, by Application (%) (2019-2030)
    4.3 Global Antihyperuricemic Agents Sales Volume by Application
        4.3.1 Global Antihyperuricemic Agents Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Antihyperuricemic Agents Sales Volume, by Application (2019-2030)
        4.3.3 Global Antihyperuricemic Agents Sales Volume, by Application (%) (2019-2030)
    4.4 Global Antihyperuricemic Agents Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Antihyperuricemic Agents Sales Value by Region
        5.1.1 Global Antihyperuricemic Agents Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Antihyperuricemic Agents Sales Value by Region (2019-2024)
        5.1.3 Global Antihyperuricemic Agents Sales Value by Region (2025-2030)
        5.1.4 Global Antihyperuricemic Agents Sales Value by Region (%), (2019-2030)
    5.2 Global Antihyperuricemic Agents Sales Volume by Region
        5.2.1 Global Antihyperuricemic Agents Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Antihyperuricemic Agents Sales Volume by Region (2019-2024)
        5.2.3 Global Antihyperuricemic Agents Sales Volume by Region (2025-2030)
        5.2.4 Global Antihyperuricemic Agents Sales Volume by Region (%), (2019-2030)
    5.3 Global Antihyperuricemic Agents Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Antihyperuricemic Agents Sales Value, 2019-2030
        5.4.2 North America Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Antihyperuricemic Agents Sales Value, 2019-2030
        5.5.2 Europe Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Antihyperuricemic Agents Sales Value, 2019-2030
        5.6.2 Asia Pacific Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Antihyperuricemic Agents Sales Value, 2019-2030
        5.7.2 South America Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Antihyperuricemic Agents Sales Value, 2019-2030
        5.8.2 Middle East & Africa Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Antihyperuricemic Agents Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Antihyperuricemic Agents Sales Value
        6.2.1 Key Countries/Regions Antihyperuricemic Agents Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Antihyperuricemic Agents Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Antihyperuricemic Agents Sales Value, 2019-2030
        6.3.2 United States Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Antihyperuricemic Agents Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Antihyperuricemic Agents Sales Value, 2019-2030
        6.4.2 Europe Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Antihyperuricemic Agents Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Antihyperuricemic Agents Sales Value, 2019-2030
        6.5.2 China Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Antihyperuricemic Agents Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Antihyperuricemic Agents Sales Value, 2019-2030
        6.6.2 Japan Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Antihyperuricemic Agents Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Antihyperuricemic Agents Sales Value, 2019-2030
        6.7.2 South Korea Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Antihyperuricemic Agents Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Antihyperuricemic Agents Sales Value, 2019-2030
        6.8.2 Southeast Asia Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Antihyperuricemic Agents Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Antihyperuricemic Agents Sales Value, 2019-2030
        6.9.2 India Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Antihyperuricemic Agents Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Takeda Pharmaceuticals
        7.1.1 Takeda Pharmaceuticals Company Information
        7.1.2 Takeda Pharmaceuticals Introduction and Business Overview
        7.1.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Takeda Pharmaceuticals Antihyperuricemic Agents Product Offerings
        7.1.5 Takeda Pharmaceuticals Recent Development
    7.2 Hikma
        7.2.1 Hikma Company Information
        7.2.2 Hikma Introduction and Business Overview
        7.2.3 Hikma Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Hikma Antihyperuricemic Agents Product Offerings
        7.2.5 Hikma Recent Development
    7.3 Wockhardt
        7.3.1 Wockhardt Company Information
        7.3.2 Wockhardt Introduction and Business Overview
        7.3.3 Wockhardt Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Wockhardt Antihyperuricemic Agents Product Offerings
        7.3.5 Wockhardt Recent Development
    7.4 West Ward Pharmaceuticals
        7.4.1 West Ward Pharmaceuticals Company Information
        7.4.2 West Ward Pharmaceuticals Introduction and Business Overview
        7.4.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 West Ward Pharmaceuticals Antihyperuricemic Agents Product Offerings
        7.4.5 West Ward Pharmaceuticals Recent Development
    7.5 Rhea Pharmaceutical
        7.5.1 Rhea Pharmaceutical Company Information
        7.5.2 Rhea Pharmaceutical Introduction and Business Overview
        7.5.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Rhea Pharmaceutical Antihyperuricemic Agents Product Offerings
        7.5.5 Rhea Pharmaceutical Recent Development
    7.6 Medinova
        7.6.1 Medinova Company Information
        7.6.2 Medinova Introduction and Business Overview
        7.6.3 Medinova Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Medinova Antihyperuricemic Agents Product Offerings
        7.6.5 Medinova Recent Development
    7.7 Odan Laboratories
        7.7.1 Odan Laboratories Company Information
        7.7.2 Odan Laboratories Introduction and Business Overview
        7.7.3 Odan Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 Odan Laboratories Antihyperuricemic Agents Product Offerings
        7.7.5 Odan Laboratories Recent Development
    7.8 TEIJIN
        7.8.1 TEIJIN Company Information
        7.8.2 TEIJIN Introduction and Business Overview
        7.8.3 TEIJIN Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 TEIJIN Antihyperuricemic Agents Product Offerings
        7.8.5 TEIJIN Recent Development
    7.9 Casper Pharma
        7.9.1 Casper Pharma Company Information
        7.9.2 Casper Pharma Introduction and Business Overview
        7.9.3 Casper Pharma Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Casper Pharma Antihyperuricemic Agents Product Offerings
        7.9.5 Casper Pharma Recent Development
    7.10 Dr. Reddys Laboratories
        7.10.1 Dr. Reddys Laboratories Company Information
        7.10.2 Dr. Reddys Laboratories Introduction and Business Overview
        7.10.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 Dr. Reddys Laboratories Antihyperuricemic Agents Product Offerings
        7.10.5 Dr. Reddys Laboratories Recent Development
    7.11 Teva
        7.11.1 Teva Company Information
        7.11.2 Teva Introduction and Business Overview
        7.11.3 Teva Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.11.4 Teva Antihyperuricemic Agents Product Offerings
        7.11.5 Teva Recent Development
    7.12 Zydus Pharmaceuticals
        7.12.1 Zydus Pharmaceuticals Company Information
        7.12.2 Zydus Pharmaceuticals Introduction and Business Overview
        7.12.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.12.4 Zydus Pharmaceuticals Antihyperuricemic Agents Product Offerings
        7.12.5 Zydus Pharmaceuticals Recent Development
    7.13 Mylan
        7.13.1 Mylan Company Information
        7.13.2 Mylan Introduction and Business Overview
        7.13.3 Mylan Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.13.4 Mylan Antihyperuricemic Agents Product Offerings
        7.13.5 Mylan Recent Development
    7.14 Sun Pharmaceutical
        7.14.1 Sun Pharmaceutical Company Information
        7.14.2 Sun Pharmaceutical Introduction and Business Overview
        7.14.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.14.4 Sun Pharmaceutical Antihyperuricemic Agents Product Offerings
        7.14.5 Sun Pharmaceutical Recent Development
    7.15 APOTEX
        7.15.1 APOTEX Company Information
        7.15.2 APOTEX Introduction and Business Overview
        7.15.3 APOTEX Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.15.4 APOTEX Antihyperuricemic Agents Product Offerings
        7.15.5 APOTEX Recent Development
    7.16 NorthStar Healthcare
        7.16.1 NorthStar Healthcare Company Information
        7.16.2 NorthStar Healthcare Introduction and Business Overview
        7.16.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.16.4 NorthStar Healthcare Antihyperuricemic Agents Product Offerings
        7.16.5 NorthStar Healthcare Recent Development
    7.17 Ipca Laboratories
        7.17.1 Ipca Laboratories Company Information
        7.17.2 Ipca Laboratories Introduction and Business Overview
        7.17.3 Ipca Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.17.4 Ipca Laboratories Antihyperuricemic Agents Product Offerings
        7.17.5 Ipca Laboratories Recent Development
    7.18 Accord Healthcare
        7.18.1 Accord Healthcare Company Information
        7.18.2 Accord Healthcare Introduction and Business Overview
        7.18.3 Accord Healthcare Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.18.4 Accord Healthcare Antihyperuricemic Agents Product Offerings
        7.18.5 Accord Healthcare Recent Development
    7.19 Gentec Pharmaceutical Group
        7.19.1 Gentec Pharmaceutical Group Company Information
        7.19.2 Gentec Pharmaceutical Group Introduction and Business Overview
        7.19.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.19.4 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Offerings
        7.19.5 Gentec Pharmaceutical Group Recent Development
    7.20 Indoco Remedies
        7.20.1 Indoco Remedies Company Information
        7.20.2 Indoco Remedies Introduction and Business Overview
        7.20.3 Indoco Remedies Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.20.4 Indoco Remedies Antihyperuricemic Agents Product Offerings
        7.20.5 Indoco Remedies Recent Development
    7.21 Lupin
        7.21.1 Lupin Company Information
        7.21.2 Lupin Introduction and Business Overview
        7.21.3 Lupin Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.21.4 Lupin Antihyperuricemic Agents Product Offerings
        7.21.5 Lupin Recent Development
    7.22 Waterstone Pharmaceuticals
        7.22.1 Waterstone Pharmaceuticals Company Information
        7.22.2 Waterstone Pharmaceuticals Introduction and Business Overview
        7.22.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.22.4 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Offerings
        7.22.5 Waterstone Pharmaceuticals Recent Development
    7.23 ALP Pharm
        7.23.1 ALP Pharm Company Information
        7.23.2 ALP Pharm Introduction and Business Overview
        7.23.3 ALP Pharm Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.23.4 ALP Pharm Antihyperuricemic Agents Product Offerings
        7.23.5 ALP Pharm Recent Development
    7.24 Jiangsu Hengrui Medicine
        7.24.1 Jiangsu Hengrui Medicine Company Information
        7.24.2 Jiangsu Hengrui Medicine Introduction and Business Overview
        7.24.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.24.4 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Offerings
        7.24.5 Jiangsu Hengrui Medicine Recent Development
    7.25 Jiangsu Wanbang Biopharmaceuticals
        7.25.1 Jiangsu Wanbang Biopharmaceuticals Company Information
        7.25.2 Jiangsu Wanbang Biopharmaceuticals Introduction and Business Overview
        7.25.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.25.4 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Offerings
        7.25.5 Jiangsu Wanbang Biopharmaceuticals Recent Development
    7.26 Hangzhou Zhuyangxin Pharmaceutical
        7.26.1 Hangzhou Zhuyangxin Pharmaceutical Company Information
        7.26.2 Hangzhou Zhuyangxin Pharmaceutical Introduction and Business Overview
        7.26.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.26.4 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Offerings
        7.26.5 Hangzhou Zhuyangxin Pharmaceutical Recent Development
    7.27 YiChang HEC ChangJiang Pharmaceutical
        7.27.1 YiChang HEC ChangJiang Pharmaceutical Company Information
        7.27.2 YiChang HEC ChangJiang Pharmaceutical Introduction and Business Overview
        7.27.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.27.4 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Offerings
        7.27.5 YiChang HEC ChangJiang Pharmaceutical Recent Development
    7.28 KPC Pharmaceuticals
        7.28.1 KPC Pharmaceuticals Company Information
        7.28.2 KPC Pharmaceuticals Introduction and Business Overview
        7.28.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.28.4 KPC Pharmaceuticals Antihyperuricemic Agents Product Offerings
        7.28.5 KPC Pharmaceuticals Recent Development
    7.29 Tonghua Limin
        7.29.1 Tonghua Limin Company Information
        7.29.2 Tonghua Limin Introduction and Business Overview
        7.29.3 Tonghua Limin Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.29.4 Tonghua Limin Antihyperuricemic Agents Product Offerings
        7.29.5 Tonghua Limin Recent Development
    7.30 Beijing Jialin Pharmaceutical
        7.30.1 Beijing Jialin Pharmaceutical Company Information
        7.30.2 Beijing Jialin Pharmaceutical Introduction and Business Overview
        7.30.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2019-2024)
        7.30.4 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Offerings
        7.30.5 Beijing Jialin Pharmaceutical Recent Development

 8 Industry Chain Analysis
    8.1 Antihyperuricemic Agents Industrial Chain
    8.2 Antihyperuricemic Agents Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Antihyperuricemic Agents Sales Model
        8.5.2 Sales Channel
        8.5.3 Antihyperuricemic Agents Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Antihyperuricemic Agents Market Trends
    Table 2. Antihyperuricemic Agents Market Drivers & Opportunity
    Table 3. Antihyperuricemic Agents Market Challenges
    Table 4. Antihyperuricemic Agents Market Restraints
    Table 5. Global Antihyperuricemic Agents Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Antihyperuricemic Agents Revenue Market Share by Company (2019-2024)
    Table 7. Global Antihyperuricemic Agents Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Antihyperuricemic Agents Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Antihyperuricemic Agents Price by Company (2019-2024) & (US$/Unit)
    Table 10. Key Manufacturers Antihyperuricemic Agents Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Antihyperuricemic Agents Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Antihyperuricemic Agents
    Table 13. Global Antihyperuricemic Agents Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihyperuricemic Agents as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Antihyperuricemic Agents Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Antihyperuricemic Agents Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Antihyperuricemic Agents Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Antihyperuricemic Agents Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Antihyperuricemic Agents Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Antihyperuricemic Agents Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Antihyperuricemic Agents Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Antihyperuricemic Agents Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Antihyperuricemic Agents Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Antihyperuricemic Agents Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Antihyperuricemic Agents Price by Type (2019-2024) & (US$/Unit)
    Table 27. Global Antihyperuricemic Agents Price by Type (2025-2030) & (US$/Unit)
    Table 28. Global Antihyperuricemic Agents Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Antihyperuricemic Agents Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Antihyperuricemic Agents Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Antihyperuricemic Agents Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Antihyperuricemic Agents Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Antihyperuricemic Agents Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Antihyperuricemic Agents Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Antihyperuricemic Agents Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Antihyperuricemic Agents Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Antihyperuricemic Agents Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Antihyperuricemic Agents Price by Application (2019-2024) & (US$/Unit)
    Table 39. Global Antihyperuricemic Agents Price by Application (2025-2030) & (US$/Unit)
    Table 40. Global Antihyperuricemic Agents Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Antihyperuricemic Agents Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Antihyperuricemic Agents Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Antihyperuricemic Agents Sales Value by Region (2019-2024) & (%)
    Table 44. Global Antihyperuricemic Agents Sales Value by Region (2025-2030) & (%)
    Table 45. Global Antihyperuricemic Agents Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Antihyperuricemic Agents Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Antihyperuricemic Agents Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Antihyperuricemic Agents Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Antihyperuricemic Agents Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Antihyperuricemic Agents Average Price by Region (2019-2024) & (US$/Unit)
    Table 51. Global Antihyperuricemic Agents Average Price by Region (2025-2030) & (US$/Unit)
    Table 52. Key Countries/Regions Antihyperuricemic Agents Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Antihyperuricemic Agents Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Antihyperuricemic Agents Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Antihyperuricemic Agents Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Antihyperuricemic Agents Sales Volume, (2025-2030) & (K Units)
    Table 57. Takeda Pharmaceuticals Company Information
    Table 58. Takeda Pharmaceuticals Introduction and Business Overview
    Table 59. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 60. Takeda Pharmaceuticals Antihyperuricemic Agents Product Offerings
    Table 61. Takeda Pharmaceuticals Recent Development
    Table 62. Hikma Company Information
    Table 63. Hikma Introduction and Business Overview
    Table 64. Hikma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 65. Hikma Antihyperuricemic Agents Product Offerings
    Table 66. Hikma Recent Development
    Table 67. Wockhardt Company Information
    Table 68. Wockhardt Introduction and Business Overview
    Table 69. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 70. Wockhardt Antihyperuricemic Agents Product Offerings
    Table 71. Wockhardt Recent Development
    Table 72. West Ward Pharmaceuticals Company Information
    Table 73. West Ward Pharmaceuticals Introduction and Business Overview
    Table 74. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 75. West Ward Pharmaceuticals Antihyperuricemic Agents Product Offerings
    Table 76. West Ward Pharmaceuticals Recent Development
    Table 77. Rhea Pharmaceutical Company Information
    Table 78. Rhea Pharmaceutical Introduction and Business Overview
    Table 79. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 80. Rhea Pharmaceutical Antihyperuricemic Agents Product Offerings
    Table 81. Rhea Pharmaceutical Recent Development
    Table 82. Medinova Company Information
    Table 83. Medinova Introduction and Business Overview
    Table 84. Medinova Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 85. Medinova Antihyperuricemic Agents Product Offerings
    Table 86. Medinova Recent Development
    Table 87. Odan Laboratories Company Information
    Table 88. Odan Laboratories Introduction and Business Overview
    Table 89. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 90. Odan Laboratories Antihyperuricemic Agents Product Offerings
    Table 91. Odan Laboratories Recent Development
    Table 92. TEIJIN Company Information
    Table 93. TEIJIN Introduction and Business Overview
    Table 94. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 95. TEIJIN Antihyperuricemic Agents Product Offerings
    Table 96. TEIJIN Recent Development
    Table 97. Casper Pharma Company Information
    Table 98. Casper Pharma Introduction and Business Overview
    Table 99. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 100. Casper Pharma Antihyperuricemic Agents Product Offerings
    Table 101. Casper Pharma Recent Development
    Table 102. Dr. Reddys Laboratories Company Information
    Table 103. Dr. Reddys Laboratories Introduction and Business Overview
    Table 104. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 105. Dr. Reddys Laboratories Antihyperuricemic Agents Product Offerings
    Table 106. Dr. Reddys Laboratories Recent Development
    Table 107. Teva Company Information
    Table 108. Teva Introduction and Business Overview
    Table 109. Teva Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 110. Teva Antihyperuricemic Agents Product Offerings
    Table 111. Teva Recent Development
    Table 112. Zydus Pharmaceuticals Company Information
    Table 113. Zydus Pharmaceuticals Introduction and Business Overview
    Table 114. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 115. Zydus Pharmaceuticals Antihyperuricemic Agents Product Offerings
    Table 116. Zydus Pharmaceuticals Recent Development
    Table 117. Mylan Company Information
    Table 118. Mylan Introduction and Business Overview
    Table 119. Mylan Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 120. Mylan Antihyperuricemic Agents Product Offerings
    Table 121. Mylan Recent Development
    Table 122. Sun Pharmaceutical Company Information
    Table 123. Sun Pharmaceutical Introduction and Business Overview
    Table 124. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 125. Sun Pharmaceutical Antihyperuricemic Agents Product Offerings
    Table 126. Sun Pharmaceutical Recent Development
    Table 127. APOTEX Company Information
    Table 128. APOTEX Introduction and Business Overview
    Table 129. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 130. APOTEX Antihyperuricemic Agents Product Offerings
    Table 131. APOTEX Recent Development
    Table 132. NorthStar Healthcare Company Information
    Table 133. NorthStar Healthcare Introduction and Business Overview
    Table 134. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 135. NorthStar Healthcare Antihyperuricemic Agents Product Offerings
    Table 136. NorthStar Healthcare Recent Development
    Table 137. Ipca Laboratories Company Information
    Table 138. Ipca Laboratories Introduction and Business Overview
    Table 139. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 140. Ipca Laboratories Antihyperuricemic Agents Product Offerings
    Table 141. Ipca Laboratories Recent Development
    Table 142. Accord Healthcare Company Information
    Table 143. Accord Healthcare Introduction and Business Overview
    Table 144. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 145. Accord Healthcare Antihyperuricemic Agents Product Offerings
    Table 146. Accord Healthcare Recent Development
    Table 147. Gentec Pharmaceutical Group Company Information
    Table 148. Gentec Pharmaceutical Group Introduction and Business Overview
    Table 149. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 150. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Offerings
    Table 151. Gentec Pharmaceutical Group Recent Development
    Table 152. Indoco Remedies Company Information
    Table 153. Indoco Remedies Introduction and Business Overview
    Table 154. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 155. Indoco Remedies Antihyperuricemic Agents Product Offerings
    Table 156. Indoco Remedies Recent Development
    Table 157. Lupin Company Information
    Table 158. Lupin Introduction and Business Overview
    Table 159. Lupin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 160. Lupin Antihyperuricemic Agents Product Offerings
    Table 161. Lupin Recent Development
    Table 162. Waterstone Pharmaceuticals Company Information
    Table 163. Waterstone Pharmaceuticals Introduction and Business Overview
    Table 164. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 165. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Offerings
    Table 166. Waterstone Pharmaceuticals Recent Development
    Table 167. ALP Pharm Company Information
    Table 168. ALP Pharm Introduction and Business Overview
    Table 169. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 170. ALP Pharm Antihyperuricemic Agents Product Offerings
    Table 171. ALP Pharm Recent Development
    Table 172. Jiangsu Hengrui Medicine Company Information
    Table 173. Jiangsu Hengrui Medicine Introduction and Business Overview
    Table 174. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 175. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Offerings
    Table 176. Jiangsu Hengrui Medicine Recent Development
    Table 177. Jiangsu Wanbang Biopharmaceuticals Introduction and Business Overview
    Table 178. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 179. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Offerings
    Table 180. Jiangsu Wanbang Biopharmaceuticals Recent Development
    Table 181. Jiangsu Wanbang Biopharmaceuticals Company Information
    Table 182. Hangzhou Zhuyangxin Pharmaceutical Company Information
    Table 183. Hangzhou Zhuyangxin Pharmaceutical Introduction and Business Overview
    Table 184. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 185. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Offerings
    Table 186. Hangzhou Zhuyangxin Pharmaceutical Recent Development
    Table 187. YiChang HEC ChangJiang Pharmaceutical Company Information
    Table 188. YiChang HEC ChangJiang Pharmaceutical Introduction and Business Overview
    Table 189. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 190. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Offerings
    Table 191. YiChang HEC ChangJiang Pharmaceutical Recent Development
    Table 192. KPC Pharmaceuticals Company Information
    Table 193. KPC Pharmaceuticals Introduction and Business Overview
    Table 194. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 195. KPC Pharmaceuticals Antihyperuricemic Agents Product Offerings
    Table 196. KPC Pharmaceuticals Recent Development
    Table 197. Tonghua Limin Company Information
    Table 198. Tonghua Limin Introduction and Business Overview
    Table 199. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 200. Tonghua Limin Antihyperuricemic Agents Product Offerings
    Table 201. Tonghua Limin Recent Development
    Table 202. Beijing Jialin Pharmaceutical Company Information
    Table 203. Beijing Jialin Pharmaceutical Introduction and Business Overview
    Table 204. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 205. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Offerings
    Table 206. Beijing Jialin Pharmaceutical Recent Development
    Table 207. Key Raw Materials Lists
    Table 208. Raw Materials Key Suppliers Lists
    Table 209. Antihyperuricemic Agents Downstream Customers
    Table 210. Antihyperuricemic Agents Distributors List
    Table 211. Research Programs/Design for This Report
    Table 212. Key Data Information from Secondary Sources
    Table 213. Key Data Information from Primary Sources
List of Figures
    Figure 1. Antihyperuricemic Agents Product Picture
    Figure 2. Global Antihyperuricemic Agents Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Antihyperuricemic Agents Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Antihyperuricemic Agents Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Antihyperuricemic Agents Sales Price (2019-2030) & (US$/Unit)
    Figure 6. Antihyperuricemic Agents Report Years Considered
    Figure 7. Global Antihyperuricemic Agents Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Antihyperuricemic Agents Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Antihyperuricemic Agents Revenue in 2023
    Figure 10. Antihyperuricemic Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Inhibit Uric Acid Production Agents Picture
    Figure 12. Promote Uric Acid Excretion Agents Picture
    Figure 13. Others Picture
    Figure 14. Global Antihyperuricemic Agents Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Antihyperuricemic Agents Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Global Antihyperuricemic Agents Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 17. Global Antihyperuricemic Agents Sales Volume Market Share by Type, 2023 & 2030
    Figure 18. Global Antihyperuricemic Agents Price by Type (2019-2030) & (US$/Unit)
    Figure 19. Product Picture of Hospital Pharmacies
    Figure 20. Product Picture of Retail Pharmacies
    Figure 21. Product Picture of Online Pharmacies
    Figure 22. Global Antihyperuricemic Agents Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Antihyperuricemic Agents Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global Antihyperuricemic Agents Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 25. Global Antihyperuricemic Agents Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global Antihyperuricemic Agents Price by Application (2019-2030) & (US$/Unit)
    Figure 27. North America Antihyperuricemic Agents Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe Antihyperuricemic Agents Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific Antihyperuricemic Agents Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America Antihyperuricemic Agents Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa Antihyperuricemic Agents Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa Antihyperuricemic Agents Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions Antihyperuricemic Agents Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions Antihyperuricemic Agents Sales Volume (%), (2019-2030)
    Figure 39. United States Antihyperuricemic Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States Antihyperuricemic Agents Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe Antihyperuricemic Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe Antihyperuricemic Agents Sales Value by Application (%), 2023 VS 2030
    Figure 45. China Antihyperuricemic Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
    Figure 47. China Antihyperuricemic Agents Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan Antihyperuricemic Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan Antihyperuricemic Agents Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea Antihyperuricemic Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea Antihyperuricemic Agents Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia Antihyperuricemic Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia Antihyperuricemic Agents Sales Value by Application (%), 2023 VS 2030
    Figure 57. India Antihyperuricemic Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India Antihyperuricemic Agents Sales Value by Type (%), 2023 VS 2030
    Figure 59. India Antihyperuricemic Agents Sales Value by Application (%), 2023 VS 2030
    Figure 60. Antihyperuricemic Agents Industrial Chain
    Figure 61. Antihyperuricemic Agents Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed

Description

Antihyperuricemic agents are also called anti-gout drugs. These drugs correct the overproduction or underexcretion of uric acid.

The global market for Antihyperuricemic Agents was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

Market Segmentation